The lupus anticoagulant/antiphospholipid syndrome

Annual Review of Medicine

Volumn 47, Issue , 1996, Pages 533-553

  Shapiro, Sandor S ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

2 glycoprotein I; Anticardiolipin

Indexed keywords

ACETYLSALICYLIC ACID; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID; PROTEIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; CLINICAL FEATURE; FETUS WASTAGE; HEMOSTASIS; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK; THROMBOCYTOPENIA; THROMBOSIS;

ABORTION, HABITUAL; ANTIBODIES, ANTICARDIOLIPIN; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; INFANT, NEWBORN; LUPUS COAGULATION INHIBITOR; PREGNANCY; RISK FACTORS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0029969339     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.47.1.533     Document Type: Review

References (182)

1. McNeil HP, Chesterman CN, Krilis SA. 1991. Immunology and clinical importance of antiphospholipid antibodies. Adv. Immunol. 49:193-280
2. Exner T. 1994. Some recent developments with lupus anticoagulants. Blood Coagul. Fibrinolysis 5:281-89
3. Harris EN, Pierangeli SS. 1994. Antiphospholipid antibodies and the antiphospholipid syndrome. Springer Sem. Immunopathol. 16:223-45
4. Lockwood CJ, Rand JH. 1994. The immunobiology and obstetrical consequences of antiphospholipid antibodies. Obstet. Gynecol. Surv. 49:432-41
5. Shapiro SS, Essex DW. 1994. Lupus anticoagulant syndromes. In Acute Rheumatic and Immunological Diseases: Management of the Critically III Patient with Immunologic Disease, ed. BF Mandell, pp. 257-75. New York/Basel/Hong Kong: Marcel Dekker. 619 pp.
6. Triplett DA. 1995. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb. Res. 78:1-31
7. Gharavi AE, Sammaritano LR, Wen J, et al. 1994. Characteristics of human immunodeficiency virus and chlorpromazine induced antiphospholipid antibodies: effect of beta 2 glycoprotein I on binding to phospholipid. J. Rheumatol 21:94-99
8. Matsuda J, Saitoh N, Gohchi K, et al. 1994. Detection of beta-2-glycoprotein-I-dependent antiphospholipid antibodies and anti-beta-2-glycoprotein-I antibody in patients with systemic lupus erythematosus and in patients with syphilis. Int. Arch. Allergy Immunol. 103:239-44
9. Ordi-Ros J, Selva-O'Callaghan A, Monegal-Ferran F, et al. 1994. Prevalence, significance, and specificity of antibodies to phospholipids in Q fever. Clin. Inf. Dis. 18:213-18
10. Roubey RAS, Pratt CW, Buyon JP, Winfield JB. 1992. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon β2-glycoprotein I. J. Clin. Invest. 90:1100-4
11. Galli M, Comfurius P, Barbui T, et al. 1992. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb. Haemost. 68:297-300
12. Galli M, Finazzi G, Bevers EM, Barbui T. 1995. Kaolin clotting time and dilute Russell Viper venon time distinguish between prothrombin-dependent and β2-glycoprotein I-dependent antiphospholipid antibodies. Blood 86:617-23
13. Bevers EM, Galli M, Barbui T, et al. 1991. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb. Haemost. 66:629-32
14. Permpikul P, Rao LV, Rapaport SI. 1994. Functional and binding studies of the roles of prothrombin and β2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 83:2878-92
15. Forastiero RR, Cerrato GS, Carreras LO. 1994. Evaluation of recently described tests for detection of the lupus anticoagulant. Thromb. Haemost. 72:728-33
16. Triplett DA. 1994. New diagnostic strategies for lupus anticoagulants and antiphospholipid antibodies. Haemostasis 24: 155-64
17. Amiral J, Larrivaz I, Cluzeau D, Adam M. 1994. Standardization of immunoassays for antiphospholipid antibodies with β2GPI and role of other phospholipid co-factors. Haemostasis 24:191-203
18. Reber G, Arvieux J, Comby E, et al. 1995. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. Thromb. Haemost. 73: 444-52
19. Shi W, Krilis SA, Chong BH, et al. 1990. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust. NZ J. Med. 20:231-36
20. Vila P, Hernandez MC, Lopez-Fernadez MF, Battle J. 1994. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb. Haemost. 72:209-13
21. Jones JV, Eastwood BJ, Jones E, et al. 1995. Antiphospholipid antibodies in a healthy population: methods for estimating the distribution. J. Rheumatol. 22:55-61
22. Harris EN, Spinnato JA. 1991. Should anticardiolipin tests be performed in otherwise healthy pregnant women? Am. J. Obstet. Gynecol. 165:1272-77
23. Aoki K, Matsuura E, Sasa H, et al. 1994. beta2-glycoprotein I-dependent and -independent anticardiolipin antibodies in healthy pregnant women. Hum. Reprod. 9: 1849-51
24. Derksen RHWM, Hasselaar P, Blokzijl L, et al. 1988. Coagulation screen is more specific than the antiphospholipid antibody ELISA in defining a thrombotic subset of lupus patients. Ann. Rheum. Dis. 47: 364-71
25. Hasselaar P, Derksen RHWM, Blokzijl L, et al. 1989. Risk factors for thrombosis in lupus patients. Ann. Rheum. Dis. 48: 933-40
26. Montes de Oca MA, Babron MC, Bletry O, et al. 1991. Thrombosis in systemic lupus erythematosus: a French collaborative study. Arch. Dis. Child. 66:713-17
27. Ames PRJ, Pyke S, Iannaccone L, Brancaccio V. 1995. Antiphospholipid antibodies, haemostatic variables and thrombosis - a survey of 144 patients. Thromb. Haemost. 73:768-73
28. Escalante A, Brey RL, Braxton MD, et al. 1995. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am. J. Med. 98:559-65
29. Morgan M, Downs K, Chesterman CN, Biggs JC. 1993. Clinical analysis of 125 patients with the lupus anticoagulant. Aust. NZ J. Med. 23:151-56
30. Drenkard C, Villa AR, Alarcon-Segovia D, Perez-Vazquez ME. 1994. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J. Rheumatol. 21:1067-72
31. Ford SE, Kennedy L, Ford PM. 1994. Clinicopathologic correlations of antiphospholipid antibodies. An autopsy study. Arch. Pathol Lab. Med. 118:491-95
32. Leung W-H, Wong K-L, Lau C-P, et al. 1990. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am. J. Med. 89:411-19
33. Brenner B, Blumenfeld Z, Markiewicz W, Reisner SA. 1991. Cardiac involvement in patients with primary antiphospholipid syndrome. J. Am. Coll. Cardiol. 18:931-36
34. Jouhikainen T, Pohjola-Sintonen S, Stephansson E. 1994. Lupus anticoagulant and cardiac manifestations in systemic lupus erythematosus. Lupus 3:167-72
35. Metz D, Jolly D, Graciet-Richard J, et al. 1994. Prevalence of valvular involvement in systemic lupus erythematosus and association with antiphospholipid syndrome: a matched echocardiographic study. Cardiology 85:129-36
36. Hamsten A, Bjorkholm M, Norberg R, de Faire U. 1986. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1:113-16
37. Diaz MN, Becker RC. 1994. Anticardiolipin antibodies in patients with unstable angina. Cardiology 84:380-84
38. Vaarala O, Manttari M, Manninen V, et al. 1995. Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91: 23-27
39. Ginsburg KS, Liang MH, Newcomer L, et al. 1992. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann. Int. Med. 117:997-1002
40. Tohgi H, Takahashi H, Kashiwaya M, et al. 1994. The anticardiolipin antibody in elderly stroke patients: its effects on stroke types, recurrence, and the coagulation- fibrinolysis system. Acta Neurol. Scand. 90: 86-90
41. Muir KW, Squire IB, Alwan W, Lees KR. 1994. Anticardiolipin antibodies in an unselected stroke population. Lancet 344: 452-56
42. Angelini L, Ravelli A, Caporali R, et al. 1994. High prevalence of antiphospholipid antibodies in children with idiopathic cerebral ischemia. Pediatrics 94:500-3
43. Kalashnikova LA, Nasonov EL, Kushekbaeva AE, Gracheva LA. 1990. Anticardiolipin antibodies in Sneddon's syndrome. Neurology 40:464-67
44. Aznar J, Villa P, Yaya R, Ferrando F, Estelles A. 1993, Sneddon's syndrome and antiphospholipid antibodies. Thromb. Res. 69:555-60
45. Fetoni V, Berti E, Cecca E, et al. 1994. Sneddon's syndrome: clinical and immunohistochemical findings. Clin. Neurol. Neurosurg. 96:310-13
46. Lavalle C, Pizarro S, Drenkard C, et al. 1990. Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J. Rheumatol. 17:34-37
47. Guzman J, Cabral AR, Cabiedes J, et al. 1994. Antiphospholipid antibodies in patients with idiopathic autoimmune haemolytic anemia. Autoimmunity 18:51-56
48. Becker JC, Winkler B, Klingert S, Brocker E-B. 1994. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 73:1621-24
49. Hassell KL, Kressin DC, Neumann A, et al. 1994. Correlation of antiphospholipid antibodies and protein S deficiency with thrombosis in HIV-infected men. Blood Coagul. Fibrinolysis 5:455-62
50. Carreno L, Monteagudo I, Lopez-Longo FJ, et al. 1994. Anticardiolipin antibodies in pediatric patients with human immunodeficiency virus. J. Rheumatol. 21: 1344-46
51. al-Saeed A, Makris M, Malia RG, et al. 1994. The development of antiphospholipid antibodies in haemophilia is linked to infection with hepatitis C. Br. J. Haematol. 88:845-18
52. Facer CA, Agiostratidou G. 1994. High levels of anti-phospholipid antibodies in uncomplicated and severe Plasmodium falciparum and in P. vivax malaria. Clin. Exp. Immunol. 95:304-9
53. Hojnik M, Gilburd B, Ziporen L, et al. 1994. Anticardiolipin antibodies in infections are heterogenous in their dependency on beta 2-glycoprotein I: analysis of anticardiolipin antibodies in leprosy. Lupus 3: 515-21
54. Hunt JE, McNeil HP, Morgan GJ, et al. 1992. A phospholipid-β2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1:75-82
55. Chong BH, Brighton TC, Chesterman CN. 1995. Antiphospholipid antibodies and platelets. Semin. Thromb. Hemost. 21: 76-84
56. Jouhikainer T, Kekomaki R, Leirisalo-Repo M, et al. 1990. Platelet autoantibodies detected by immunoblotting in systemic lupus erythematosus: association with the lupus anticoagulant,and with history of thrombosis and thombocytopenia. Eur. J.Haematol. 44:234-39
57. Out HJ, de Groot PG, van Vliet M, et al. 1991. Antibodies to platelets in patients with anti-phospholipid antibodies. Blood 77:2655-59
58. Stasi R, Stipa E, Masi M, et al. 1994. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 84:4203-8
59. Eroglu GE, Scopelitis E. 1994. Antinuclear and antiphospholipid antibodies in healthy women with recurrent spontaneous abortion. Am. J. Reprod. Immunol. 31:1-6
60. Bocciolone L, Meroni P, Parazzini F, et al. 1994. Antiphospholipid antibodies and risk of intraulerine late fetal death. Acta Obstet. Gynecol. Scand. 73:389-92
61. Clifford K, Rai R, Watson H, Regan L. 1994. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum. Reprod. 9:1328-32
62. DeCarolis S, Caruso A, Ferrazzani S, et al. 1994. Poor pregnancy outcome and anticardiolipin antibodies. Fetal Diag. Ther. 9:296-99
63. MacLean MA, Cumming GP, McCall F, et al. 1994. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br. J.Obstet. Gynaecol. 101: 103-6
64. Ozawa N, Makino T, Matsubayashi H, et al. 1994. beta2-GpI-dependent and independent binding of anticardiolipin antibodies in patients with recurrent spontaneous abortions. J. Clin. Lab. Anal. 8:255-59
65. Aoki K, Dudkiewicz AB, Matsuura E, et al. 1995. Clinical significance of beta 2-glycoprotein I-dependent anticardiolipin antibodies in the reproductive autoimmune failure syndrome: correlation with conventional antiphospholipid antibody detection systems. Am. J. Obstet. Gynecol. 172: 926-31
66. Ginsberg JS, Demers C, Brill-Edwards P, et al. 1993. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state. Blood 81:2958-63
67. Falanga A, Ofosu FA, Cortelazzo S, et al. 1994. Hemostatic system activation in patients with lupus anticoagulant and essential thrombocytopenia. Semin. Thromb. Hemost. 20:324-27
68. Nakase T, Wada H, Minamikawa K, et al. 1994. Increased activated protein C-protein C inhibitor complex level in patients positive for lupus anticoagulant. Blood Coagul. Fibrinolysis 5:173-77
69. Ferro D, Quintarelli C, Valesini G, Violi F. 1994. Lupus anticoagulant and increased thrombin generation in patients with systemic lupus erythematosus. Blood 83:304
70. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. 1994. Induction of tissue factor-like activity in monocytes by anticardiolipin antibodies. J Immunol. 153:1328-32
71. de Prost D, Ollivier V, Ternisien C, Chollet-Martin S. 1990. Increased monocyte procoagulant activity independent of the lupus anticoagulant in patients with systemic lupus erythematosus. Thromb. Haemost. 64: 216-21
72. Marciniak E, Romond EH. 1989. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 74:2426-32
73. Matsuda J, Gohchi K, Gotoh M, et al. 1994. Plasma concentrations of total/free and functional protein S are not decreased in systemic lupus erythematosus patients with lupus anticoagulant and/or antiphospholipid antibodies. Ann. Hematol. 69:311-15
74. Parke AL, Weinstein RE, Bona RD, Maier DB. 1992. The thrombotic diathesis associated with the presence of phospholipid antibodies may be due to low levels of free protein S. Am. J. Med. 93:49-56
75. Forastiero RR, Kordich L, Basilotta E, Carreras LO. 1994. Differences in protein S and C4b-binding protein levels in different groups of patients with antiphospholipid antibodies. Blood Coagul. Fibrinolysis 5: 609-16
76. Ginsberg JS, Demers C, Brill-Edwards P, et al. 1995. Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus. Am. J. Med.98:379-83
77. Potzsch B, Kawamura H, Preissner KT, et al. 1995. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J. Lab. Clin. Med. 125:56-65
78. Malia RG, Kitchen S, Greaves M, Preston FE. 1990. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br. J. Haematol. 76:101-7
79. Borrell N, Sala N, de Castellarnau C, et al. 1992. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb. Haemost. 68:268-72
80. Bokarewa MI, Blomback M, Egberg N, Rosen S. 1994. A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coagul. Fibrino lysis 5:37-41
81. Bokarewa MI, Bremme K, Falk G, et al. 1995. Studies on phospholipid antibodies, APC-resistance and associated mutation in the coagulation factor V gene. Thromb. Haemost. 78:193-200
82. Le DT, Griffin JH, Greengard JS, et al. 1995. Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood 85: 1704-11
83. Hunt JE, McNeil HP, Morgan GJ, et al. 1992. A phospholipid-β2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1:75-82
84. Yin D, Love T, Essex D, et al. 1992. Heterogeneity in the immunologic specificity of anticardiolipin antibodies (ACAs). Blood 80:1235
85. Wagenknecht DR, McIntyre JA. 1993. Changes in β2-glycoprotein I antigenicity induced by phospholipid binding. Thromb. Haemost. 69:361-65
86. Pengo V, Biasiolo A, Fior MG. 1995. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β2-glycoprotein I is bound to a suitable surface. Thromb. Haemost. 73: 29-34
87. Pierangeli SS, Harris EN, Davis SA, De-Lorenzo G. 1992. β2-glycoprotein I (β2GpI) enhances cardiolipin binding activity but is not the antigen for antiphospholipid antibodies. Br. J. Hematol. 82:565-70
88. Arvieux J, Roussel B, Jacob MC, Colomb MG. 1991. Measurement of anti-phospholipid antibodies by ELISA using β2-glycoprotein I as an antigen. J. Immunol. Methods 143:223-29
89. Viard J-P, Amoura Z, Bach J-F. 1992. Association of anti-β2-glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am. J. Med. 93:181-85
90. Keeling DM, Wilson AJG, Mackie IJ, et al. 1992. Some 'antiphospholipid antibodies' bind to β2-glycoprotein I in the absence of phospholipid. Br. J. Haematol. 82:571-74
91. Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. 1995. "Anticardiolipin" autoantibodies recognize β2-glycoprotein I in the absence of phospholipid. J. Immunol. 154:954-60
92. Matsuura E, Igarashi Y, Yasuda T, Triplett DA. 1994. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med. 179: 457-62
93. Matsuura E, Igarashi Y, Fujimoto M, et al. 1992. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin co-factor. J. Immunol. 148:3885-91
94. Martinuzzo ME, Forastiero RR, Carreras LO. 1995. Anti-β2-glycoprotein I antibodies: detection and association with thrombosis. Br. J. Hematol. 89:397-402
95. Nakamura N, Azuma C, Akamizu T, et al. 1994. Heterogeneity and diversity of IgM and IgG lupus anticoagulants in an individual with systemic lupus erythematosus. Biochem. Biophys. Res. Commun. 203: 1789-94
96. Yron I, Shohat L, Lahav J, et al. 1994. A human monoclonal IgA autoantibody - 185/12 - behaves like an autoimmune antiphospholipid antibody. Clin. Exp. Immunol. 97:187-92
97. Ichikawa K, Khamashta MA, Koike T, et al. 1994. beta 2-glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum. 37:1453-61
98. Wang M-X, Kandiah DA, Ichikawa K, et al. 1995. Epitope specificity of monoclonal anti-β2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome. J. Immunol. 155:1629-36
99. Humphries JE, Acker MN, Pinkston JE, Ruddy S. 1994. Transient lupus anticoagulant associated with prothrombin deficiency: unusual cause of bleeding in a 5-year old girl. Am. J. Pediatr. Hematol. Oncol. 16:372-76
100. Peacock NW, Levine SP. 1994. Case report: the lupus anticoagulant-hypoprothrombinemia syndrome. Am. J. Med. Sci. 307: 346-49
101. Oosting JD, Derksen RHWM, Bobbink IWG, et al. 1993. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism. Blood 81:2618-25
102. Sugi T, McIntyre JA. 1995. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 86: 3083-89
103. Smirnov MD, Triplett DT, Comp PC, et al. 1995. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J. Clin. Invest. 95:309-16
104. Staub M, Harris EN, Khamashata MH, et al. 1989. Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis. Ann. Rheum. Dis. 48: 166-69
105. Falcon CR, Hoffer AM, Carreras LO. 1990. Evaluation of the clinical and laboratory associations of antiphosphatidylethanolamine antibodies. Thromb. Res. 59:383-88
106. Karmochkine M, Cacoub P, Piette JC, et al. 1992. Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis. Clin. Exp. Rheum. 10:603-5
107. Vlachoyiannopoulos PG, Beigbeder G, Dueymes M, et al. 1993. Antibodies to phosphatidylethanolamine in antiphospholipid syndrome and systemic lupus erythematosus: their correlation with anticardiolipin antibodies and β2 glycoprotein-I plasma levels. Autoimmunity 16:245-49
108. Berrard M, Boffa MC, Karmochkine MF, et al. 1993. Plasma reactivity to hexagonal II phase phosphatidylethanolamine is more frequently associated with lupus anticoagulant than with antiphosphatidylethanolamine antibodies. J. Lab. Clin. Med. 122: 601-5
109. Horie S, Ishii H, Hara H, Kazama M. 1994. Enhancement of thrombin-thrombomodulin-catalysed protein C activation by phosphatidylethanolamine containing unsaturated fatty acids: possible physiological significance of phosphatidylethanolamine in anticoagulant activity of thrombomodulin. Biochem. J. 301:683-91
110. Vermylen J, Arnout J. 1992. Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes? J. Lab. Clin. Med. 120:10-12
111. Santoro SA. 1994. Antiphospholipid antibodies and thrombotic predisposition: underlying pathogenetic mechanisms. Blood 83:2389-91
112. Hunt JE, Adelstein S, Krilis SA. 1994. New basic aspects of the antiphospholipid syndrome. Clin. Exp. Rheumatol. 12:661-68
113. Roubey RAS. 1994. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 84:2854-67
114. Chamley LW, McKay EJ, Pattison NS. 1993. Inhibition of heparin/antithrombin III cofactor activity by anticardiolipin antibodies: a mechanism for thrombosis. Thromb. Res. 71:103-11
115. Shibata S, Harpel PC, Gharavi A, et al. 1994. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 83: 2532-40
116. Arvieux JA, Pouzul P, Roussel B, et al. 1992. Lupus- like anticoagulant properties of murine monoclonal antibodies to β2-glycoprotein I. Br. J. Haematol. 81:568-73
117. Brandt JT. 1993. Antibodies to β2-glycoprotein I inhibit phospholipid dependent coagulation reactions. Thromb. Haemost. 70:598-602
118. Kouts S, Wang M-X, Adelstein S, Krillis SA. 1995. Immunization of a rabbit with β2-glycoprotein I induces charge-dependent crossreactive antibodies that bind anionic phospholipids and have similar reactivity as autoimmune anti- phospholipid antibodies. J. Immunol. 155:958-66
119. Goldsmith GH, Pierangeli SS, Branch DW, et al. 1994. Inhibition of prothrombin activation by antiphospholipid antibodies and β2-glycoprotein I. Br. J. Haematol. 87: 548-54
120. Nomura S, Fukuhara S, Komiyama Y, et al. 1994. β2- glycoprotein I and anticardio lipin antibody influence factor Xa generation but not factor Xa binding to platelet-derived microparticles. Thromb. Haemost. 71:526-30
121. Bancsi LF, van der Linden IK, Bertina RM. 1992. β2-glycoprotein I deficiency and the risk of thrombosis. Thromb. Haemost. 67: 649-53
122. Rock G, Chauhan K, Jamieson GA, Tandon NN. 1994. Anti-CD36 antibodies in patients with lupus anticoagulant and thrombotic complications. Br. J. Haematol. 88: 878-80
123. Fabris F, Steffan A, Cordiano I. 1994. Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia. Eur. J. Haematol. 53: 232-36
124. Arvieux J, Roussel B, Pouzol P, Colomb MG. 1993. Platelet activating properties of murine monoclonal antibodies to p2-glycoprotein I. Thromb. Haemost. 70:336-41
125. Shi W, Beng H, Chong H, Chesterman CN. 1993. β2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood 81:1255-62
126. Vazquez-Mellado J, Llorente L, Richaud-Patin Y, Alarcon-Segovia D. 1994. Exposure of anionic phospholipids upon platelet activation permits binding of β2-glycoprotein I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects. J. Autoimmun. 7:335-48
127. Martinuzzo ME, Maclouf J, Carreras LO, Levy-Toledano S. 1993. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb. Haemost. 70:667-71
128. Reverter J-C, Tassies D, Escolar G, et al. 1995. Effect of plasma from patients with primary antiphospholipid syndrome on platelet function in a collagen rich perfusion system. Thromb. Haemost. 73:132-37
129. Shi W, Beng H, Chong H, et al. 1993. Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity of platelets. Thromb. Haemost. 70:342-45
130. Galli M, Bevers EM, Comfurius P, et al. 1993. Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br. J. Haematol. 83:466-72
131. Lellouche F, Martinuzzo M, Said P, et al. 1991. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 78:2894-99
132. Westphal JR, Boerbooms AM, Schalkwijk CJM, et al. 1994, Anti-endothelial cell antibodies in sera of patients with autoimmune diseases: comparison between ELISA and FACS analysis. Clin. Exp. Immunol. 96:444-49
133. D'Cruz DP, Houssiau FA, Ramirez G, et al. 1991. Antibodies to endothelial cells in systemic lupus erythematosus: a potential marker for nephritis and vasculitis. Clin. Exp. Immunol. 85:254-61
134. Hasegawa I, Suzuki T, Ishii S, et al. 1994. Establishment of two distinct anticardiolipin antibody-producing cell lines from the same individual by Epstein-Barr virus transformation. Thromb. Res. 74:77-84
135. Kaise S, Watanabe H, Kasukawa R. 1994. Cross reactivity of anti-cardiolipin antibodies with glycolipids and endothelial cells. Fukushima J. Med. Sci. 40:25-37
136. McCrae KR, DeMichele AM, Samuels P, et al. 1991. Detection of endothelial cell-reactive immunoglobulin in patients with antiphospholipid antibodies. Br. J. Haematol. 79:595-605
137. Hess DC, Sheppard JC, Adams RJ. 1993. Increased immunoglobulin binding to cerebral endothelium in patients with antiphospholipid antibodies. Stroke 24:994-99
138. Lindsey NJ, Henderson FI, Malia R, et al. 1994. Inhibition of prostacyclin release by endothelial binding anticardiolipin antibodies in thrombosis-prone patients with systemic lupus erythematosus and the antiphospholipid syndrome. Br. J. Rheumatol. 33:2-4
139. Yoshio T, Masuyama J, Sumiya M, et al. 1994. Antiendothelial cell antibodies and their relation to pulmonary hypertension in systemic lupus erythematosus. J. Rheumatol. 21:2058-63
140. Watson KV, Schorer AE. 1991. Lupus anticoagulant inhibition of in vitro prostacyclin release is associated with a thrombosis-prone subset of patients. Am. J. Med. 90: 47-53
141. Oosting JD, Derksen RHWM, Blokzijl L, et al. 1992. Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity - studies in a thrombosis model. Thromb. Haemost. 68:278-84
142. Karmochkine M, Berard M, Piette J-C, et al. 1994. The effect of sera with antiphospholipid antibodies on endothelial cell procoagulant activity is dependent upon the charge of the phospholipids against which they are directed. Thromb. Res. 74:435-40
143. Lee MJ, Silver RK, O'Connell PD, Caplan MS. 1994. Endothelial cell 1-acyl-platelet-activating factor synthesis in response to anticardiolipin antibody-positive serum fractions. Prostaglandins 47:221-31
144. Nakamura N, Shidara Y, Kawaguchi N, et al. 1994. Lupus anticoagulant autoantibody induces apoptosis in umbilical vein endothelial cells: involvement of annexin V. Biochem. Biophys. Res. Commun. 205: 1488-93
145. Del Papa N, Meroni PL, Tincani A, et al. 1992. Relationship between anti-phospholipid and anti-endothelial cell antibodies: further characterization of the reactivity on resting and cytokine-activated endothelial cells. Clin. Exp. Rheumatol. 10:37-42
146. van der Zee JM, Miltenburg AMM, Siegert CEH, et al. 1994. Antiendothelial cell antibodies in systemic lupus erythematosus: enhanced antibody binding to interleukin-1-stimulated endothelium. Int. Arch. Allergy Immunol. 104:131-36
147. La Rosa L, Meroni PL, Tincani A, et al. 1994. β2 glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome. J. Rheumatol.21:1684-93
148. Chamley LW, Pattison NS, McKay EJ. 1994. Elution of anticardiolipin antibodies and their cofactor β2-glycoprotein I from the Placentae of patients with a poor obstetric history. J. Reprod. Immunol. 25:209-20
149. Lyden TW, Vogt E, Au-Kau N, et al. 1992. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. J. Reprod. Immunol. 22:1-14
150. McCrae KR, DeMichele AM, Pandhi P, et al. 1993. Detection of antitrophoblast antibodies in the sera of patients with anticardiolipin antibodies and fetal loss. Blood 82: 2730-41
151. Krikun G, Lockwood CJ, Wu X-X, et al. 1994. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta 15:601-12
152. Rand JH, Wu X-X, Guller S, et al. 1994. Reduction of annexin-V (placental anticoagulant protein I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am. J. Obstet. Gynecol. 171:1566-72
153. Gharavi AE, Aron AL. 1994. Experimental models for antiphospholipid studies. Haemostasis 24:204-7
154. Shoenfeld Y. 1994. The significance of experimental models of systemic lupus erythematosus and antiphospholipid syndrome induced by idiotypic manipulation. Isr. J. Med. Sci. 30:10-18
155. Pierangeli SS, Barker JH, Stikovac D, et al. 1994. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb. Haemost. 71: 670-74
156. Gharavi AE, Mellors RC, Elkon KB. 1989. IgG anti-cardiolipin antibodies in murine lupus. Clin. Exp. Immunol. 78:233-38
157. Smith HR, Hansen CL, Rose R, Canoso RT. 1990. Autoimmune MRL-lpr/lpr mice are an animal model for the secondary antiphospholipid syndrome. J. Rheumatol. 17:911-15
158. Ichikawa K, Shimada K, Nawata Y, et al. 1988. Monoclonal hybridoma anti-cardiolipin antibodies from SLE mice. Clin. Exp. Immunol. 74:110-14
159. Blank M, Cohen J, Toder V, Shoenfeld Y. 1991. Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibodies. Proc. Natl. Acad. Sci. USA 88:3069-73
160. Bakimer R, Fishman P, Blank M, et al. 1992. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J. Clin. Invest. 89:1558-63
161. Blank M, Krause I, Ben-Bassat M, Shoenfeld Y. 1992. Induction of experimental antiphospholipid syndrome associated with SLE following immunization with human monoclonal pathogenic anti-DNA idiotype. J. Autoimmun. 5:495-509
162. Gharavi AE, Sammaritano LR, Wen J, Elkon KB. 1992. Induction of antiphospholipid autoantibodies by immunization with β2 glycoprotein I (apolipoprotein H). J. Clin. Invest. 90:1105-09
163. Blank M, Faden D, Tincani A, et al. 1994. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J. Autoimmun. 7:441-55
164. Fishman P, Falach-Vaknine E, Zigelman R, et al. 1993. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J. Clin. Invest. 91:1834-37
165. Tomer Y, Blank M, Shoenfeld Y. 1994. Suppression of experimental antiphospholipid syndrome and systemic lupus erythematosus in mice by anti-CD4 monoclonal antibodies. Arthritis Rheum. 37: 1236-44
166. Shoenfeld Y, Blank M. 1994. Effect of long-acting thromboxane receptor antagonist (BMS 180,291) on experimental antiphospholipid syndrome. Lupus 3: 397-400
167. Kouts S, Wang M-X, Adelstein S, Krilis SA. 1995. Immunization of a rabbit with β2-glycoprotein I induces charge-dependent cross reactive antibodies that bind anionic phospholipids and have similar reactivity as autoimmune anti-phospholipid antibodies. J. Immunol. 155:958-66
168. Igarashi K, Umeda M, Tokita S, et al. 1991. Effective induction of anti-phospholipid and anticoagulant antibodies in normal mouse. Thromb. Res. 61:135-48
169. Rosove MH, Tabsh K, Wasserstrum N, et al. 1990. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstet. Gynecol. 75: 630-34
170. Sher G, Feinman M, Zouves C, et al. 1994. High fecundity rates following in-vitro fertilization and embryo transfer in antiphospholipid antibody seropositive women treated with heparin and aspirin. Hum. Reprod. 9:2278-83
171. Julkunen H, Jouhikainen T, Kaaja R. 1994. Fetal outcome in lupus
172. Derksen RHWM, Bruinse HW, deGroot PG, Kater L. 1994. Pregnancy in systemic lupus erythematosus: a prospective study. Lupus 3:149-55
173. Arnout J, Spitz B, Wittevrongel C, et al. 1994. High-dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: immunological changes associated with a successful outcome. Thromb. Haemost. 71: 741-47
174. Caccavo D, Vaccaro F, Ferri GM, et al. 1994. Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. J. Autoimmun. 7:537-48
175. Rosove MH, Brewer PM. 1992. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann. Intern. Med. 117:303-8
176. Derksen RH, de Groot PG, Kater L, Nieuwenhuis HK. 1993. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann. Rheum. Dis. 52:689-92
177. Ordi-Ros J, Perez-Peman P, Monasterio J. 1994. Clinical and therapeutic aspects associated to phospholipid binding antibodies (lupus anticoagulant and anticardiolipin antibodies). Haemostasis 24:165-74
178. Khamashta MA, Cuadrado MJ, Mujic F, et al. 1995. The management of thrombosis in the antiphospholipid-antibody syndrome. N. Engl. J. Med. 332:993-1028
179. Nasr SZ, Parke AL. 1995. Thrombosis in the antiphospholipid-antibody syndrome (letter). Blood 333:666
180. Silver RM, Draper ML, Scott JR, et al. 1994. Clinical consequences of antiphospholipid antibodies: an historic cohort study. Obstet. Gynecol. 83:372-77
181. Owren PA. 1955. Long-term dicumarol treatment in cardiovascular disease - technique and results. Proc. 1st Int.Conf. Thrombosis Embolism, Basel, Switzerland, pp. 1085-94
182. Rapaport SI, The Le D. 1995. Thrombosis in the antiphospholipid-antibody syndrome (letter). Blood 333:665